Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Arcturus Therapeutics Holdings - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ARCT
Nasdaq
8731
https://arcturusrx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Arcturus Therapeutics Holdings
Arcturus Therapeutics Holdings Inc (ARCT) Insider Sells Shares
- Mar 28th, 2024 5:34 am
Arcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ...
- Mar 22nd, 2024 5:26 am
Arcturus Therapeutics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
- Mar 17th, 2024 1:50 pm
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
- Mar 9th, 2024 6:09 pm
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript
- Mar 8th, 2024 5:10 pm
Q4 2023 Arcturus Therapeutics Holdings Inc Earnings Call
- Mar 8th, 2024 11:54 am
Arcturus Therapeutics Reports Fiscal Year 2023 Financial Results and Pipeline Developments
- Mar 8th, 2024 3:42 am
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
- Mar 7th, 2024 10:10 pm
Arcturus Therapeutics: Q4 Earnings Snapshot
- Mar 7th, 2024 9:21 pm
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
- Mar 7th, 2024 9:01 pm
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
- Mar 4th, 2024 6:23 pm
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
- Feb 26th, 2024 8:20 pm
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
- Feb 26th, 2024 2:00 pm
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
- Feb 22nd, 2024 1:30 pm
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
- Feb 21st, 2024 6:04 pm
3 Tech Stocks That Could Be Multibaggers in the Making: February Edition
- Feb 20th, 2024 9:39 pm
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
- Feb 20th, 2024 2:00 pm
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
- Feb 5th, 2024 1:30 pm
18 High Growth Low PE Stocks
- Jan 23rd, 2024 9:16 am
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
- Dec 21st, 2023 1:00 pm
Scroll